Juvenile myelomonocytic leukemia radiation therapy

Revision as of 16:40, 9 August 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Juvenile myelomonocytic leukemia Microchapters

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Epidemiology & Demographics

Risk Factors

Screening

Causes of Juvenile myelomonocytic leukemia

Differentiating Juvenile myelomonocytic leukemia from other Diseases

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

MRI

CT

Echocardiography or Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgical Therapy

Radiation Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Juvenile myelomonocytic leukemia radiation therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Juvenile myelomonocytic leukemia radiation therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Juvenile myelomonocytic leukemia radiation therapy

CDC on Juvenile myelomonocytic leukemia radiation therapy

Juvenile myelomonocytic leukemia radiation therapy in the news

Blogs on Juvenile myelomonocytic leukemia radiation therapy

to Hospitals Treating Juvenile myelomonocytic leukemia

Risk calculators and risk factors for Juvenile myelomonocytic leukemia radiation therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Radiation/Radiotherapy

Radiation to the spleen does not generally result in a decrease in spleen size or reduction of platelet transfusion requirement.

Conditioning regimen

The COG JMML Study involves 8 rounds of total-body irradiation (TBI) and doses of cyclophosphamide to prepare the JMML child’s body for bone marrow transplant. Use of TBI is controversial, though, because of the possibility of late side-effects such as slower growth, sterility, learning disabilities, and secondary cancers, and the fact that radiation can have devastating effects on very young children. It is used in this study, however, due to the concern that chemotherapy alone might not be enough to kill dormant JMML cells. The EWOG-MDS JMML Study includes busulfan in place of TBI due to its own research findings that appeared to show that busulfan was more effective against leukemia in JMML than TBI. The EWOG-MDS study also involves cyclophosphamide and melphalan in its conditioning regimen.

References

fi:Juveniili myelomonosyyttileukemia


Template:WikiDoc Sources